TriSalus Life Sciences, Inc. (TLSI)
(Delayed Data from NSDQ)
$4.20 USD
+0.02 (0.48%)
Updated Aug 4, 2025 03:59 PM ET
After-Market: $4.21 +0.01 (0.24%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TLSI 4.20 +0.02(0.48%)
Will TLSI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TLSI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TLSI
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)
TLSI: What are Zacks experts saying now?
Zacks Private Portfolio Services
OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates
TerrAscend Corp. (TSNDF) Reports Q1 Loss, Lags Revenue Estimates
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates
Other News for TLSI
TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference | ...
TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call | TLSI ...
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent ...
TriSalus Life Sciences management to meet virtually with Lake Street
Lake Street Keeps Their Buy Rating on TriSalus Life Sciences (TLSI)